Pacira Pharmaceuticals

Pacira Pharmaceuticals is one of the...

• Russell 3000.

Pacira Pharmaceuticals is a company listed under the stock ticker PCRX (US).

View the org chart displaying its 23 main executives

Most searched biographies at Pacira Pharmaceuticals

• Frank Lee, Chief Executive Officer and Director
• Gary Pace, Director
• Mark Kronenfeld, Director

Popular executive movements at Pacira Pharmaceuticals

• Frank Lee will join the company as Chief Executive Officer and Director on Jan. 2, 2024  (posted on December 22 2023).
• Paul Hastings who is Lead Independent Director, will be promoted to Chairman of the Board on Jan. 2, 2024  (posted on December 22 2023).
• Alethia Young has joined the company as Director  (posted on October 11 2023).

Click here to view some more movements at Pacira Pharmaceuticals

Create your alert
to follow the executive moves at Pacira Pharmaceuticals.

Pacira Pharmaceuticals has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• MedMen has filed for bankruptcy protection  (posted on April 28 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma
• Lucia Aleotti - Director at Menarini Group

Learn more about the Pharmaceuticals industry >

Press releases by Pacira Pharmaceuticals

• Pacira BioSciences Reports Second Quarter 2022 Financial Results | Pacira BioSciences, Inc.
• Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference | Pacira BioSciences, Inc.
• Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022 | Pacira BioSciences, Inc.
• Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million | Pacira BioSciences, Inc.
• National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse | Pacira BioSciences, Inc.
• Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022 | Pacira BioSciences, Inc.
• Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference | Pacira BioSciences, Inc.
• Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022 | Pacira BioSciences, Inc.
• Pacira BioSciences to Present at Two Healthcare Conferences in May | Pacira BioSciences, Inc.
• Pacira BioSciences Reports First Quarter 2022 Financial Results | Pacira BioSciences, Inc.
• View more press releases Close

Social media about Pacira Pharmaceuticals

• Pacira Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Pacira Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Frank Lee

Call Pacira Pharmaceuticals at +1 973...

View the org chart

Register to receive your alert

Report an error